Navigation Links
Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance
Date:12/11/2008

apsing remitting MS.

-- Tasisulam (ASAP) - Currently in Phase II, tasisulam has exhibited properties resembling a targeted agent as well as a cytotoxic. The company is testing the anti-tumor activity of tasisulam in several ongoing Phase II studies. Potential registration studies could begin in 2009.

-- GLP-Fc - A Phase II/III adaptive, seamless trial was initiated in early 2008 for the company's leading proprietary GLP-1 asset, a novel Fc-fusion protein GLP-1 analog, or GLP-Fc. Two other Phase II studies of GLP-Fc are also underway in over 400 patients. The company expects safety and efficacy data from the first of these two studies to become available in 2009.

-- Inflammation - The company has made a strong commitment to research in inflammation, as evidenced by four leading internal antibody candidates. IL-17 is progressing into larger Phase II clinical trials in the near future, while IL-23 entered Phase I in 2008. The company also anticipates initiating larger Phase II clinical trials for its BAFF antagonist antibody and IL-1beta in the near future.

Dr. Eric Rowinsky, M.D., executive vice president and chief medical officer of Lilly's wholly-owned subsidiary ImClone Systems, reviewed the numerous additional indications being pursued for Erbitux, as well as the later-stage oncology compounds currently in development.

-- ERBITUX(R) - In addition to its approved indications, Erbitux is also being studied in numerous cancer types, including colorectal, head and neck, non-small cell lung, gastric and esophageal.

-- IMC-1121B is a fully-human monoclonal antibody that targets the vascular endothelial growth factor (VEGF) receptor. Phase II studies are underway for metastatic melanoma, renal, liver, ovarian, prostate and non-small cell lung cancers. Metastatic breast cancer is in Phase III testing, while Phase III testing in gastric cancer is expected to begin in 20
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... Aug. 26, 2015  The Diabetes Research Institute ... of Miami Miller School of Medicine, announced today ... to test for the first time a novel ... This FDA approved Phase I/II study builds upon ... is an important first step toward the development ...
(Date:8/26/2015)... Aug. 26, 2015 Intrexon Corporation (NYSE: ... the closing of its previously announced public offering of ... underwriters of their option to purchase an additional 731,707 ... of $41.00 per share.  The exercise of the underwriters, ... stock sold by Intrexon to 5,609,756 shares and increased ...
(Date:8/26/2015)... -- China Cord Blood Corporation (NYSE: CO ) ... of cord blood collection, laboratory testing, hematopoietic stem cell ... the Company has been informed that Magnum Opus 2 ... Mr. Yuen Kam, chairman of the board of directors ... "Shares") of  Excellent China Healthcare Investment Limited ("KKR SPV") ...
(Date:8/26/2015)... SPRINGS, Florida , August 26, 2015 /PRNewswire/ ... of the biggest factors fueling the optimism in ... approvals, M&A,s, collaborations and life sciences advancements.  Active ... developments are Pressure BioSciences, Inc. (OTCQB: PBIO), Sequenom, ... (NASDAQ: SRPT ), Raptor Pharmaceutical Corp. (NASDAQ: ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
... Pittsburgh-based Foundation,Radiology Group (FRG), a full-service ... diagnostic images for hospitals,announced today that James ... the,position of Chief Medical Officer. The appointment ... nationwide network of radiology physician groups to,provide ...
... Ill., April 15 , What and When, ... (Carotid,intima-media tHICkness in Atherosclerosis using pioGlitazOne) published,today in ... (CIMT) with ACTOS(R) (pioglitazone HCl) was,associated with increased ... compared to glimepiride., The increased effect on ...
... Also Sign Manufacturing and Distribution Agreement, ... Ranbaxy,Pharmaceuticals Inc. (RPI), a wholly owned ... that it has reached several,agreements with AstraZeneca. ... The third agreement pertains to Omeprazole 40mg,tablets, ...
Cached Biology Technology:James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group 2James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group 3New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 2New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 3Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 2Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 3
(Date:8/6/2015)... and TELTOW, Germany , August ... Siggraph Conference, SensoMotoric Instruments (SMI) shows the ... , based on Epson,s Moverio BT-200 see-through ... platform. With this new solution, unprecedented quality and efficiency ... interaction with context-sensitive displays. For the first time, professionals ...
(Date:8/5/2015)... , August 5, 2015 According ... Access Management Market by Software, Services, Vertical (BFSI, Airport, IT ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Market globally into various segments. The global PIAM Market ... to $546.2 Million by 2019, at a CAGR of ...
(Date:8/5/2015)... The biosensors market is proving highly attractive ... newer sectors, and development of devices resulting in higher ... seen the entry of multiple participants each year with ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) Recent ... Global Biosensors Market ( http://www.frost.com/nee9 ), finds that ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... of Long Beach and Riverside are responsible for a significant ... air pollution and ship emissions on the disease has likely ... California (USC). The study, which appears in an ... , estimated that nine percent of all childhood asthma cases ...
... Oklahoma at Norman has received more than $10 ... part of the federal stimulus program, bringing thetotal ... to $23 million. Thirty-three projects achieved stimulus ... "The university has thoughtfully undertaken a systematic approach ...
... (Nasdaq: AWRE ), a leading supplier of broadband technology ... quarter ended September 30, 2009. , Michael ... we announced an agreement to sell our DSL and home ... being spun out of Infineon. This transaction represents the ...
Cached Biology News:USC study finds big air pollution impacts on local communities 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7
PPIF Antibody...
Glutamate Receptor 5/1a...
... Rabbit monoclonal [EP282Y] to Asparagine ... all tested applications). ... corresponding to residues in the ... Entrez GeneID: ...
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: